Amarin Corporation plc stock performance trend indicates that the stock price has rallied 5.79% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 3.13% . Looking at the past 52 week period, the stock price is up at 128.47% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Amarin Corporation plc has a positive value of 62.3 compared to overall market.Amarin Corporation plc is having a Relative Strength Index of 53.98 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Stocks of Amarin Corporation plc (NASDAQ:AMRN) rallied by 3.79% during the past week but lost 6.27% on a 4-week basis. The company has outperformed the S&P 500 by 3.54% in the past week but underperformed the index by 7.34% in the last 4 weeks.
For the current week, the company shares have a recommendation consensus of Buy. Amarin Corporation plc (NASDAQ:AMRN) : On Friday heightened volatility was witnessed in Amarin Corporation plc (NASDAQ:AMRN) which led to swings in the share price. The stock opened for trading at $3.26 and hit $3.38 on the upside , eventually ending the session at $3.29, with a gain of 0.92% or 0.03 points. The heightened volatility saw the trading volume jump to 1,802,577 shares. The 52-week high of the share price is $3.65 and the company has a market cap of $895 million. The 52-week low of the share price is at $1.37 .
Company has reported several Insider transactions to the SEC, on Nov 10, 2016, Joseph T Kennedy (General Counsel) sold 122,358 shares at 3.04 per share price.On Feb 3, 2016, John F Thero (CEO) purchased 25,000 shares at 1.37 per share price.
Amarin Corporation plc (ADR) Last issued its quarterly earnings results on Feb 28, 2017. The company reported $-0.10 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-0.08. The company had revenue of $38.40 million for the quarter, compared to analysts expectations of $36.13 million. The companys revenue was up 45.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.10 EPS.
Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.